

### Why Trabecular Micro-Bypass Surgery?


There is increasingly broad clinical recognition that glaucoma is a surgical disease where targeted intervention can help restore physiological outflow:

- Increased resistance to aqueous humor outflow through the trabecular meshwork is the primary source of elevated intraocular pressure (IOP) in open-angle glaucoma<sup>1</sup>
- 50% – 75% of total resistance to aqueous humor outflow is in the juxtacanalicular tissue of the trabecular meshwork<sup>2</sup>

### Precision-engineered for increased predictability

A wide flange at the base of the iStent *inject*® W is designed to:

- Enhance visibility
- Facilitate seamless implantation
- Provide observable positioning confirmation
- Deliver procedural consistency and predictability



### Injection system optimises control

- Ergonomic design includes an overall matte finish with molded-in grip texture on the sides, for increased comfort and control
- Enhanced insertion sleeve retraction button facilitates delivery of two iStent *inject* W stents




### iStent *inject*® W represents the next generation of Glaukos trabecular micro-bypass technology:

- Re-establishes physiological outflow<sup>9</sup>
- Proven to safely and effectively reduce IOP<sup>9</sup>
- Consistent, predictable procedure with next-generation stent and delivery system design
- Can reduce or eliminate drug burden<sup>8</sup>
- Indicated for patients undergoing stand-alone glaucoma surgery or combination glaucoma & cataract surgery
- Developed by Glaukos Corporation, the corporate founder of Micro-Invasive Glaucoma Surgery (MIGS)
- An elegant procedure with a safety profile similar to cataract surgery
  - Conjunctiva sparing
  - No Mytomycin C
  - No bleb management

### Ordering Information

- Order Number: G2-W
- Telephone: +1 949 367 9600
- Fax: +1 949 367 9984
- Website: [www.glaukos.com](http://www.glaukos.com)



GLAUKOS CORPORATION  
229 AVENIDA FABRICANTE • SAN CLEMENTE, CA • 92672 • USA  
tel +1 949 367 9600 • fax +1 949 367 9984 • [www.glaukos.com](http://www.glaukos.com)

GLAUKOS®  
Transforming Glaucoma Therapy

**INDICATION FOR USE.** The iStent *inject*® W is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent *inject*® W can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery.

**REFERENCES:** 1. Grant WM. Experimental aqueous perfusion in enucleated human eyes. *Arch Ophthalmol*. 1963;69:783–801. 2. Rosenquist R, Epstein D, Melamed S et al. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. *Curr Eye Res*. 1989;8:1233–1240. 3. Saheb H, Ahmed I. Micro-Invasive glaucoma surgery: current perspectives and future directions. *Curr Opin Ophthalmol*. 2012;23:96–104. 4. Bahler C, Hann C, Fjeld T, et al. Second-generation Trabecular Meshwork Bypass Stent (iStent *inject*®) Increases Outflow Facility in Cultured Human Anterior Segments. *Am J Ophthalmol*. 2012;153:1206–1213. 5. Brubaker RF. The flow of aqueous humor in the human eye. *Trans Am Ophthalmol Soc*. 1982;80:391–474. 6. iStent *inject*® W Trabecular Micro-Bypass System: Directions for Use, San Clemente, Calif: Glaukos Corporation. 7. Fea A, et al. *Clin Ophthalmol*. 2014;8:875–882. 8. Hengerer FH. Personal experience with second-generation trabecular micro-bypass stents in combination with cataract surgery in patients with glaucoma: 3-year follow-up. ASCRS 2018 Presentation. 9. Lindstrom R, Lewis R, Hornbeak H, Voskanyan L, Giamporcaro JE, Hovanessian J, Sarkisian S. Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. *Adv Ther* 2016;33:2082-2090.


©2019 Glaukos Corporation. All trademarks are the property of their respective owners. iStent *inject*® and Glaukos are registered trademarks of Glaukos Corporation. PM-EU-0058

iStent  
*inject*® W



EVOLVING DESIGN. ADVANCING PREDICTABILITY.

Proven performance. Unmatched safety. Clinical excellence.



# iStent inject W


## TRABECULAR MICRO-BYPASS SYSTEM

### iStent inject W delivers two preloaded trabecular micro-bypass stents with a single entry

Built on proven Glaukos trabecular micro-bypass technology, iStent inject W reduces IOP by bypassing the primary source of resistance to improve aqueous outflow through the conventional pathway. iStent inject W is an elegant procedure for the treatment of OAG:

- Targeted placement of stents helps to restore conventional outflow
- In-vitro perfusion analyses demonstrate increased facility of outflow and IOP reductions with multiple stents<sup>4</sup>
- Both iStent and iStent inject W have sufficient capacity to produce steady-state physiological outflow<sup>5,6</sup>

### Outcomes following implantation of two second-generation trabecular micro-bypass stents in patients with open-angle glaucoma on one medication<sup>9</sup>




- Mean unmedicated IOP decreased by 41% at 18M<sup>9</sup>
- 100% of eyes DROP FREE at 12M, 98% of eyes DROP FREE at 18M<sup>9</sup>
- 67% of eyes  $\leq 15$ mmHg at 12M, 100% of eyes  $\leq 18$ mmHg at 12M<sup>9</sup>
- No intraoperative or postoperative adverse events observed, related to iStent inject W

### Implantation of two trabecular bypass stents – without the benefit of cataract surgery – has been proven in prospective clinical trials to:


- Lower IOP to  $< 15$ mmHg<sup>7</sup>
- Reduce medication burden via a unique two-stent approach<sup>7</sup>

### iStent inject W as Sole Procedure vs. Two Medications in POAG<sup>7</sup>




### Sustained Medication Reduction<sup>8</sup>

- 37% reduction in mean IOP
- 100% of patients with IOP  $\leq 18$  mmHg



### iStent inject W Stent Specifications

A central inlet and multiple flow outlets optimise flow and collector channel access.




**Enhanced insertion sleeve retraction button**  
Facilitates delivery of two iStent inject W stents




**Ergonomic design**  
Overall matte finish with molded-in-grip texture on the sides, for increased comfort and control

#### iStent inject W stents




Made of implant grade titanium and coated with heparin

#### Insertion tube with window



Optimises visualisation of stents during implantation

#### Insertion sleeve tip



Reshaped tip for ease of insertion